Delcath Systems, Inc. (NASDAQ:DCTH – Get Rating) Director Steven A. J. Salamon purchased 6,000 shares of Delcath Systems stock in a transaction on Thursday, May 12th. The stock was purchased at an average price of $4.90 per share, for a total transaction of $29,400.00. Following the completion of the transaction, the director now owns 29,424 shares of the company’s stock, valued at $144,177.60. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
Shares of DCTH stock opened at $4.83 on Friday. Delcath Systems, Inc. has a 1 year low of $4.30 and a 1 year high of $13.50. The firm’s 50 day moving average is $6.14 and its 200-day moving average is $7.46. The company has a current ratio of 5.23, a quick ratio of 4.99 and a debt-to-equity ratio of 1.26.
Delcath Systems (NASDAQ:DCTH – Get Rating) last announced its earnings results on Tuesday, May 10th. The company reported ($1.00) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.12). Delcath Systems had a negative return on equity of 209.38% and a negative net margin of 764.84%. During the same quarter last year, the business earned ($1.04) EPS. Equities research analysts anticipate that Delcath Systems, Inc. will post -3.15 earnings per share for the current fiscal year.
A number of research firms have commented on DCTH. StockNews.com began coverage on shares of Delcath Systems in a research report on Friday. They issued a “sell” rating on the stock. Canaccord Genuity Group reduced their target price on shares of Delcath Systems from $24.00 to $20.00 and set a “buy” rating on the stock in a research report on Monday, April 11th.
About Delcath Systems (Get Rating)
Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.
- Get a free copy of the StockNews.com research report on Delcath Systems (DCTH)
- The Three Most Upgraded Stocks You Can Buy Now
- MarketBeat: Week in Review 5/9 – 5/13
- Is Electronic Arts (NASDAQ: EA) Suddenly A Safe Haven?
- Beyond Meat Stock Value is Improving
- The Travel Sector Is Getting Upgraded
Receive News & Ratings for Delcath Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Delcath Systems and related companies with MarketBeat.com's FREE daily email newsletter.